Tony Huge

Can MK-677 Make You Taller? What the Research Shows: Tony Huge’s Video Guide

Table of Contents

Did MK-677 make Tony Huge taller? No. Wider, yes, but he started at 30 with closed growth plates. He also watched a 17-year-old grow an inch in under three months on it. This video is his attempt to reconcile those two observations with the research: the only placebo-controlled growth hormone height trial, the single seven-day MK-677 study in children, the growth plate biology that decides everything, the rat study that said no, and the cortisol counterweight nobody discussing this seems to consider.

Video: Can MK-677 Make You Taller? What the Human Research Actually Shows. Published August 18, 2026. Watch on YouTube.

What the video covers

Timestamps below are approximate, placed from the transcript against the 14-and-a-half-minute runtime.

Start with what is proven to work

Tony grounds the question in the one intervention with real data. Doctors give short children injectable growth hormone, and this is a case where mainstream medicine works. He cites what he calls the short kids trial, Journal of Clinical Endocrinology and Metabolism, 2004, the only placebo-controlled one that exists: some children got real growth hormone, some got fake injections, nobody knew which, and they were followed 4.4 years to adult height. The treated children finished 3.7 cm taller, about an inch and a half. Tony’s reaction is that the number is not insignificant, but look at what it cost: 4.4 years of injections in children with wide-open growth plates under supervision, at over $35,000 an inch.

That is the system MK-677 pushes on. Growth hormone goes up, the liver makes IGF-1, IGF-1 reaches the growth plates. In the best adult study, a full year on MK-677, growth hormone rose 1.8 times and IGF-1 rose 1.5 times, and the effect held all year. So the hypothesis is reasonable: same system, same hormone, pushed the same way.

The one study in children, and why nobody followed it up

There is exactly one study that gave MK-677 to children. Tony cites it as Clinical Pharmacology and Therapeutics, 2001: 18 growth-hormone-deficient children before puberty, given the compound for seven days. IGF-1 went up, confirming the drug works in children the way it works in adults. Nobody measured height, because a week is too short, and the authors closed by writing that the compound was ready to be tested for its effect on growth. That was 2001. The growth study was never published.

“It’s not a question of science. It’s a question of money. Nobody funds a trial that they can’t profit from.”

Tony Huge, approx. 05:50

Tony’s explanation is the incentive structure. Injectable growth hormone is a prescription product with a company behind it. At $35,000 an inch, an oral compound that matched it would be a threat to that revenue, and the people holding those products have every reason not to run the comparison.

Growth plates keep their own clock

The mechanism that decides the whole question is not hormonal. Tony explains that the growth plate, a strip of cartilage near the ends of the long bones, has a set number of cell divisions in it. Every time you grow, you spend some. When they are used up, the plate closes, cartilage is replaced by solid bone, and nothing remains in the body whose job is to make you taller. The countdown is not run by hormones; the plate keeps its own clock regardless of how much growth hormone is present. That is why more growth hormone into a closed plate does nothing. There is nothing left to divide.

It also explains his own experience. Once the plates are closed, growth hormone and IGF-1 stop working on height but keep working on every other responsive tissue, which is why more growth hormone made his hands, feet, and frame thicker and wider without adding a millimeter of height. He adds an observation from travel that he frames as inference rather than data: in places with widespread nutrient deficiency, particularly protein, people are visibly shorter, and higher protein intake raises IGF-1. If someone is genuinely height-deficient relative to their genetic ceiling, growth hormone signaling might close that gap. It will not push anyone past the ceiling.

The rat said no, with a caveat

Tony’s line is that unmeasured is not the same as disproven, and an absent study is a blank space rather than evidence against. But someone did measure growth on MK-677, in rats, over six weeks: no increase in body length, bone length, or growth plate width. The difference he flags is that in the rats the drug stopped working. Their bodies stopped producing growth hormone because of the feedback loop. In the human one-year study, it kept working. He wonders aloud what a cycled protocol would have shown in rats, and notes nobody will fund that experiment either.

A study in young healthy men found total daily growth hormone did not rise on MK-677, which Tony attributes to those men already producing near their maximum. Against that, he describes research he supervised in men and women aged 22 to 45, where 20 mg of MK-677 produced the same growth hormone area under the curve as 5 IU of pharmaceutical growth hormone. The area under the curve matters because growth hormone comes out in pulses, so a single blood draw tells you almost nothing. Neither of those is a phase 3 trial, and he says so.

The cortisol counterweight

Here is the part Tony thinks everyone discussing MK-677 and height has skipped. The same one-year trial that showed the growth hormone and IGF-1 increase also showed MK-677 raises cortisol. Cortisol is catabolic, it breaks tissue down rather than building it, and in children it is known to work against growing taller. So MK-677 is pushing growth in one direction and pulling it back in another, and anyone serious about the growth question would want to address the cortisol side, which he describes as simple to do with available interventions.

Now the 17-year-old. Tony did watch him grow an inch in under three months. What nobody knows is whether he would have grown it anyway, or whether MK-677 compressed a year’s growth into a shorter window for the same net height. At 17, the average boy has reached 97.6% of his final height, with about 4 cm, an inch and a half, still coming. The inch Tony saw sits inside the margin of what would likely have happened regardless. And that person did nothing about cortisol.

Cheat Sheet Pivot

What Tony reported and what the cited studies used. He states this is not medical advice and is a review of published research.

  • Tony has run MK-677 for 13 years starting at age 30, supervising research subjects on it the whole time. Height: unchanged. Width and tissue thickness: increased.
  • The adult one-year trial: growth hormone up 1.8 times, IGF-1 up 1.5 times, cortisol also up.
  • The pediatric study: seven days, 18 growth-hormone-deficient children, IGF-1 confirmed to rise, height not measured.
  • Tony’s supervised comparison: 20 mg MK-677 matched 5 IU of pharmaceutical growth hormone on area under the curve in adults 22 to 45.
  • Where he lands: with closed plates, typically somewhere between 16 and 19 with bone age mattering more than birthday, no dose and no compound makes anyone taller. With open plates, the mechanism says it might, with zero human studies confirming it, one rat study saying no, and the cortisol question untested.
  • On blood sugar, the side effect everyone raises: Tony reports his glucose never rose and his insulin sensitivity held because he combined MK-677 with Slin pills, a product he helped design, from the start.

MK-677 and the growth hormone secretagogues are indexed in the Miracle Molecules Cheat Sheet. For Tony’s own 12-week blood work on the compound, read MK-677 (Ibutamoren) Honest Review: 12 Weeks, Full Bloodwork, Real Results. For his earlier reaction to children being given growth hormone for height, see Kids Using Growth Hormone for Height: Tony Huge Weighs In.

Where the evidence stops

Tony closes on the injury risk that comes with the same tissue everyone wants to stimulate. There is a growth plate at the top of the thigh bone and inside the hip joint, and under heavy growth hormone stimulation those plates can slip out of position, an injury that requires surgery. In the largest study, over 36,000 children on prescription growth hormone, the risk was 3.5 times higher and climbed with treatment duration. That was growth hormone, not MK-677, but he expects the net effect to be the same, and he frames it as something to raise with a doctor.

Beyond that, the honest summary is short. No human study has measured height on MK-677. The pediatric follow-up promised in 2001 never appeared. The rat study is negative but confounded by a feedback loop humans do not show. Tony’s 17-year-old is one anecdote inside the range of normal growth. MK-677 is not FDA approved, and he expects the question to be answered eventually by a newer patentable secretagogue rather than by MK-677 itself.

Keep going

For how MK-677 compares to injectable secretagogues, read Hexarelin vs Ipamorelin: Which GH Peptide Fits Which Goal. Companion articles reach the tonyhuge.is email list first, and the growth hormone archive is at tonyhuge.is.

Popular Category